Pictet Asset Management
OCUL icon

Pictet Asset Management’s Ocular Therapeutix OCUL Stock Holding History

Pictet Asset Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$268K Sell
27,272
-335,324
-92% -$3.04M ﹤0.01% 1824
2026
Q1 		$2.71M Buy
362,596
+335,324
+1,230% +$3.2M ﹤0.01% 851
2025
Q4 		$331K Buy
27,272
+11,656
+75% +$142K ﹤0.01% 1655
2025
Q3 		$183K Sell
15,616
-7,756
-33% -$92.7K ﹤0.01% 1900
2025
Q2 		$217K Buy
23,372
+3,398
+17% +$26.6K ﹤0.01% 1791
2025
Q1 		$146K Hold
19,974
– – ﹤0.01% 1861
2024
Q4 		$171K Hold
19,974
– – ﹤0.01% 1888
2024
Q3 		$174K Buy
19,974
+5,493
+38% +$45.3K ﹤0.01% 1854
2024
Q2 		$99K Buy
+14,481
New +$89.4K ﹤0.01% 1887

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Pictet Asset Management's OCUL Position: Q2 2026 in Review

Pictet Asset Management reduced its Ocular Therapeutix (OCUL) stake by 92% in Q2 2026, selling an estimated $3.04M and leaving 27,272 shares worth $268K. The position accounts for ﹤0.01% of the portfolio, ranked #1824.

Pictet Asset Management first reported a position in OCUL in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.71M in Q1 2026. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Pictet Asset Management held 27,272 shares of Ocular Therapeutix worth $268K as of Q2 2026.
  • Pictet Asset Management sold 335,324 Ocular Therapeutix shares in Q2 2026, an estimated $3.04M.
  • Ocular Therapeutix made up ﹤0.01% of Pictet Asset Management's portfolio in Q2 2026, its #1824 holding.
  • Pictet Asset Management first reported a position in Ocular Therapeutix in Q2 2024 and has held it in 9 quarters since.
  • Pictet Asset Management's Ocular Therapeutix position peaked at $2.71M in Q1 2026.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.